Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Omthera Looks To Take Lead In Omega-3 Space, Armed With Data Showing Advantages Over Lovaza

This article was originally published in The Pink Sheet Daily

Executive Summary

Privately held New Jersey firm expects data from pivotal Phase III trial of Epanova during first half of 2012, with NDA to follow shortly.

You may also be interested in...

Amarin Aims Vascepa For The Sweet Spot Of Dyslipidemia

FDA leaves door open to modify label of Amarin’s omega-3 fatty acid therapy Vascepa prior to approval in a healthier population, says company CEO. Per the current label, triglycerides are lowered significantly with no increase in LDL cholesterol, a potential differentiating point from Pronova/Glaxo’s blockbuster EPA/DHA therapy Lovaza.

As It Soaks Up Good Trial Results, Amarin Ponders Partners - Or None

A second set of clinical trial results expands the potential market for AMR101 tenfold, triggering increased investor and partnership interest.

Amarin Version 3.0 Weighs Its Options on Promising Omega-3 Pipeline

Feisty Amarin is certainly undergoing a reincarnation.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts